文献速递浆细胞疾病

PET/CT在新诊断多发性骨髓瘤早期治疗反应评估中的应用价值

Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma.
PubMed 文献 · Blood Adv · 2022-01-01

该研究回顾性分析195例新诊断多发性骨髓瘤患者,在诊断时和治疗后6个月进行氟脱氧葡萄糖PET/CT检查,评估其作为常规血液学反应辅助指标对至下次治疗时间(TTNT)和总生存(OS)的预后价值。PET/CT阴性组较阳性组中位TTNT和OS显著延长,且在调整其他预测变量后仍保留预后意义。

要点

  • 新诊断多发性骨髓瘤患者治疗后6个月PET/CT阴性者中位TTNT和OS显著优于阳性者。
  • 在达到非常好的部分缓解(VGPR)及未达VGPR的亚组中,PET/CT阴性均与更长的中位TTNT和OS相关。
  • 调整多个其他预测变量后,PET/CT仍保留独立预后意义,为血液学反应评估提供附加价值。

核心结论

  • 治疗后6个月PET/CT阴性为新诊断多发性骨髓瘤患者带来显著预后优势,并为血液学反应评估提供显著附加价值。

研究设计与样本

  • 回顾性分析195例新诊断多发性骨髓瘤患者,诊断时及治疗后6个月均有PET/CT可用,以评估其作为常规血液学反应辅助指标对TTNT和OS的价值。

主要发现

  • 整个队列中位TTNT为24.6个月(95%CI 20.4-29.1),中位OS为79个月(95%CI 63.1-119.1)。
  • PET/CT阴性组 vs 阳性组中位TTNT为55.2 vs 17.8个月(P < .0001),阴性组较阳性组延长。
  • PET/CT阴性组 vs 阳性组中位OS为未达到 vs 60.8个月(P < .0001),阴性组较阳性组延长。
  • 在VGPR组和未达VGPR组中,PET/CT阴性均与显著延长的中位TTNT和OS相关。
  • 调整多个其他预测变量后,PET/CT仍保留预后意义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is a plasma cell malignancy that is characterized by diverse clinical presentations. Although biochemical assessment of disease activity is commonly used to monitor treatment response, findings on magnetic resonance imaging and positron emission tomography (PET)/computed tomography (CT), among other imaging modalities, have proven to harbor prognostic value. We sought to corroborate these findings by examining the prognostic significance of fluorodeoxyglucose PET/CT scanning in the setting of newly diagnosed MM. We retrospectively analyzed 195 patients with a PET/CT available at diagnosis and at 6 months posttreatment to examine their value as an adjuvant metric to conventional hematologic responses in terms of time to next treatment (TTNT) and overall survival (OS). The median TTNT and OS for the entire cohort were 24.6 months (95% confidence interval [CI], 20.4-29.1) and 79 months (95% CI, 63.1-119.1), respectively. When comparing PET/CT negative (-) with PET/CT positive (+) patients, we found significantly prolonged median TTNT (55.2 vs 17.8 months, P < .0001) and OS (unreached vs 60.8 months, P < .0001) in the former group. We then examined the additive value of PET/CT on the hematologic response achieved at 6 months and found that PET/CT (-) is associated with significantly increased median TTNT and OS for the very good partial response (VGPR) group and the less than VGPR group. Importantly, PET/CT retained prognostic significance after adjusting for multiple other predictive variables. We conclude that a PET/CT (-) at 6 months confers a significant prognostic advantage for patients with newly diagnosed MM and adds significant value to the hematologic response assessment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Charalampous C, Goel U, Broski SM, et al. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. Blood Adv. 2022. PMID: 35235951. doi:10.1182/bloodadvances.2022007052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。